12-Year-Old Gets Muscle Disease Drug After Dad's Campaign

A father from Henley-on-Thames is celebrating a victory that could change his son's life after a 16-month fight to access a groundbreaking muscle disease treatment.

Ben, 12, lives with Duchenne Muscular Dystrophy, a genetic condition that gradually weakens muscles and typically limits life expectancy to the 20s or 30s. His father Alex has spent over a year campaigning for access to Givinostat, a drug that slows the disease's progression.

That persistence just paid off. Earlier this month, the National Institute for Health and Care Excellence approved Givinostat for widespread NHS use across the country, meaning Ben and others like him can now receive the treatment.

"I'm incredibly happy with the outcome, but it has been a hard fight," Alex said. "This battle over the last 14, 16 months has pretty much brought me to my knees at times."

The drug had previously only been available through an early access program at certain NHS Trusts. Alex campaigned specifically for Ben's local trust, Oxford University Hospitals, to join the program while also pushing for broader approval.

Clinical trials show Givinostat helps slow Duchenne's progression. For Ben, who currently walks short distances but uses a wheelchair for longer trips, this could mean staying mobile much longer.

"The possibility that he would be able to walk and get out of his chair and be amongst his friends through his whole school career will have a huge positive impact on him, his mental health, his inclusion and our family as well," Alex explained.

Why This Inspires

Alex's campaign shows what determined advocacy can achieve when families refuse to accept bureaucratic delays as the final answer. His fight didn't just help Ben. The nationwide approval means children across England with Duchenne Muscular Dystrophy can now access this treatment without their families having to wage similar battles.

Oxford University Hospitals has already recruited additional staff and put governance in place to start treating eligible patients within weeks. The trust's chief medical officer Andrew Brent welcomed NICE's decision and confirmed they're ready to begin.

For Alex, the relief is profound, though he acknowledges there's still work ahead supporting other families navigating similar challenges.

One father's 16-month fight has opened doors that will stay open for countless families to come.